Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

VentriPoint Diagnostics Ltd V.VPT

Alternate Symbol(s):  VPTDF

Ventripoint Diagnostics Ltd. is a Canada-based medical device company. It is engaged in the development and commercialization of diagnostic tools to monitor patients with heart disease. It develops a suite of applications for all heart diseases and imaging modalities, including congenital heart disease, pregnancy, pulmonary hypertension, COVID-19, technically difficult imaging and cardiotoxicity in oncology patients. It provides application of artificial intelligence to echocardiography. Its flagship product, Ventripoint Medical System (VMS+), enhances echocardiography to deliver cMRI levels of accuracy for volumetric measurements and ejection fractions for all four chambers of the heart. It has developed a solution that transforms cardiac care through its 3D ECHO and MRI software. VMS products are powered by its proprietary Knowledge Based Reconstruction technology, which is the result of a decade of development and provides accurate volumetric cardiac measurements equivalent to MRI.


TSXV:VPT - Post by User

Post by canon12345on Nov 12, 2020 6:02am
922 Views
Post# 31883423

Timing is everything!

Timing is everything!I understand the disillusionment of the shareholders here. It has been a long slog to get to this point. Derisked to me is showing that enough sales have taken place to justify a belief that there is a substantial market for this product. George believes that number is  80-100 site installs. The question becomes is the new 3.0 going to achieve the break through when past versions have not? The positives are existing fda approval and current site installs at major hospitals. The negatives are it has been 10 years and past versions have not been good enough. This version is the best yet and has many advantages over past versions. So where do we stand? The 3.0 has just recently been released and is in the "acceptance or not" stage by these hospitals. It looks promising but has this product been derisked? IMO not yet but it is getting there. When will it be derisked? There is no magic date or number of sales, risk however will lower with more sales/acceptance. It is at a critical point of make or break IMO. Timing is everything in these penny stocks, each investor needs to evaluate their risk tollerance and decide if this stock is right for them. For me the risk/reward ratio is, for others it won't be. Welcome to the world of penny stocks, again timing is everything!     
<< Previous
Bullboard Posts
Next >>

USER FEEDBACK SURVEY ×

Be the voice that helps shape the content on site!

At Stockhouse, we’re committed to delivering content that matters to you. Your insights are key in shaping our strategy. Take a few minutes to share your feedback and help influence what you see on our site!

The Market Online in partnership with Stockhouse